The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study
ConditionAtrial Fibrillation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-120
SponsorTulane University
About this trial
The aim of the Correlation Of CoAGulation-Atrial Fibrillation (COAG-AF) study is to prove that an increase in pro-thrombotic biomarkers in AF is associated with an increase in AF burden.
Secondary objectives of the study are the following:
* To investigate the impact of catheter ablation on serum pro-thrombotic biomarkers in patients with AF. * To correlate coagulation biomarkers with imaging features such as, the degree of fibrosis found on Late Gadolinium Enhancement Magnetic Resonance Imaging (LGE-MRI) scans, which is a part of standard of care. * To determine baseline values of coagulation and pro-thrombotic biomarkers in the AF population and compare those baseline values with the general population values. * To compare central and peripheral thrombotic biomarkers in patients with atrial fibrillation.
Eligibility criteria
Qualifiers
Patients, male or female and older than 18 years of age.
Patients diagnosed with persistent or paroxysmal AF.
Patients that are undergoing catheter ablation at Tulane University Medical Center.
Patients that had a cardiac MRI prescribed by their physician as part of their standard of care.
Disqualifiers
Patients with coagulation disorders such as, von Willebrand disease, hemophilia, Immune Thrombocytopenic Purpura, etc.
Patients who are pregnant or breast-feeding or plan to become pregnant during the study period.
Are not surgically sterile.
Are of childbearing potential and are unwilling to practice two acceptable methods of birth control.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov